{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-23-000050","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2023-11-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.622187+00:00","generated_at":"2026-06-07T19:48:40.056328+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"confidence":"high","headline":"Altimmune reports Phase 2 obesity trial: 15.6% mean weight loss with pemvidutide 2.4 mg at Week 48","bullets":["Mean weight loss of 15.6% on 2.4 mg dose vs 2.2% placebo; near-linear trajectory at end of treatment.","Over 30% of subjects achieved ≥20% weight loss on 2.4 mg; 83.9% achieved ≥5% weight loss.","Robust reductions in serum lipids and blood pressure without cardiac safety imbalances; zero MACE events.","Discontinuation rates higher at higher doses: 19.6% (2.4 mg) vs 6.2% placebo; most due to GI AEs in first 16 weeks.","Only one drug-related SAE (vomiting at 2.4 mg); nausea/vomiting predominantly mild to moderate."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-23-000050","json":"https://secwatch.observer/filing/0001326190-23-000050.json","markdown":"https://secwatch.observer/filing/0001326190-23-000050.md","text":"https://secwatch.observer/filing/0001326190-23-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000050/0001326190-23-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000050/alt-20231130x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T19:48:40.056328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}